Table 2 Clinical characteristics of the 52 enrolled patients

Age (years)

0.350

 < 65

35 (67.3)

15 (75.0)

20 (62.5)

 65

17 (22.7)

5 (25.0)

12 (37.5)

Gender

0.508

 Male

29 (55.8)

10 (50.0)

19 (59.4)

 Female

23 (44.2)

10 (50.0)

13 (40.6)

Body mass index (kg/m²)

22.5 ± 3.5

22.8 ± 3.3

22.4 ± 3.6

0.542

Preoperative CEA level (ng/ml)

0.744

 < 5

17 (32.7)

6 (30.0)

11 (34.4)

 ≥ 5

35 (67.3)

14 (70.0)

21 (65.6)

Comorbidity

14 (26.9)

4 (20.0)

10 (31.3)

0.374

Tumour location

0.636

 Colon

42 (80.8)

15 (75.0)

27 (84.4)

 Rectum

10 (19.2)

5 (25.0)

5 (15.6)

Histology

0.289

 Adenocarcinoma

29 (55.8)

13 (65.0)

16 (50.0)

 Mucinous/signet-ring

23 (44.2)

7 (35.0)

16 (50.0)

T stage

0.287

 T3

6 (11.5)

4 (20.0)

2 (6.3)

 T4

46 (88.5)

16 (80.0)

30 (93.7)

N stage

0.506

 N0

8 (15.4)

3 (15.0)

5 (15.6)

 N1

16 (30.8)

8 (40.0)

8 (25.0)

 N2

28 (53.8)

9 (45.0)

19 (59.4)

PCI score

0.031

 < 12

32 (61.5)

16 (80.0)

16 (50.0)

 ≥ 12

20 (38.5)

4 (20.0)

16 (50.0)

PCI score

11.9 ± 5.6

9.8 ± 4.7

13.7 ± 6.4

0.006

Liver metastases

9 (17.3)

4 (20.0)

5 (15.6)

0.977

Ascites

22 (42.3)

8 (40.0)

14 (43.8)

0.790

HIPEC regimen

0.930

 Lobaplatin+oxaliplatin+raltitrexed

23 (44.2)

9 (45.0)

14 (43.8)

 Oxaliplatin+faltitrexed

29 (55.8)

11 (55.0)

18 (56.2)

CC score

0.018

 0–1

31 (59.6)

16 (80.0)

15 (46.9)

 2–3

21 (40.4)

4 (20.0)

17 (53.1)

Adjuvant chemotherapy

0.738

 Yes

44 (84.6)

16 (80.0)

28 (87.5)

 No

8 (15.4)

4 (20.0)

4 (12.5)